Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-4 Study
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Tucatinib|DRUG: Trastuzumab|DRUG: Pertuzumab
Sponsor: The Netherlands Cancer Institute
Collaborators: Seagen Inc.